Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® ...

Novavax transfers EU rights for Nuvaxovid to Sanofi, earning milestone payments and future royalties. Read more here.

In the latest close session, Novavax (NVAX) was down 4.02% at $9.08. This move lagged the S&P 500's daily gain of 0.37%. At the same time, the Dow lost 0.14%, and the tech-heavy Nasdaq gained 0.71%.

The updated 2025-2026 COVID-19 vaccines are now widely available, but with some new limitations. Who can get the shot this ...

Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding ...

The new updated COVID-19 vaccines for 2025-2026 will be available in the fall. Here are answers to some of the most common ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

Shares of Novavax fell more than 25% in after-hours trading Tuesday, following a dismal fourth quarter earnings report and a warning from the Covid vaccine maker that uncertainty over future funding ...

Novavax was an early coronavirus vaccine favorite but fell behind and missed out on the biggest revenue opportunity. Now it may enter the fall vaccine market later than rivals Pfizer and Moderna.

NEW YORK, Oct 9 (Reuters) - Vaccine maker Novavax Inc (NVAX.O), opens new tab on Monday said it has shipped millions of doses its updated COVID-19 shots to distributors after receiving the go-ahead ...

There are still more than 26 million American adults who are unvaccinated. Amid growing concerns over highly contagious omicron subvariants that are spreading around the country, Americans are set to ...